How A Celgene-Partnered Drug Trial Could Save Struggling Acceleron Pharma

Published: Jun 14, 2017

Acceleron Pharma stock rebounded Tuesday afternoon after announcing Monday that it's scrapping development of a kidney cancer drug, putting Wall Street focus squarely on a Celgene-partnered rare disease drug.

By the closing bell on the stock market today, Acceleron stock popped 5% to 29.64, after earlier falling as much as 4.8% to a nearly two-week low. Shares bounded above their 50-day moving average in the afternoon.

Back to news